Beatrice D. Darimont
Affiliations: | University of Oregon, Eugene, OR, United States |
Area:
Molecular Biology, Pharmacology, BiochemistryGoogle:
"Beatrice Darimont"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Leslie E. Schwarcz | grad student | 2006 | University of Oregon |
| Sachiko Takayama | grad student | 2006 | University of Oregon |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kahraman M, Govek SP, Nagasawa JY, et al. (2019) Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927. Acs Medicinal Chemistry Letters. 10: 50-55 |
| Joseph JD, Darimont B, Zhou W, et al. (2019) Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 8 |
| Govek SP, Bonnefous C, Julien JD, et al. (2018) Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft. Bioorganic & Medicinal Chemistry Letters |
| Kahraman M, Govek SP, Nagasawa JY, et al. (2018) Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927 Cancer Research. 78: 1648-1648 |
| Joseph JD, Darimont B, Zhou W, et al. (2016) The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 5 |
| Govek SP, Nagasawa JY, Douglas KL, et al. (2015) Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft. Bioorganic & Medicinal Chemistry Letters |
| Lai A, Kahraman M, Govek S, et al. (2015) Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. Journal of Medicinal Chemistry. 58: 4888-904 |
| Joseph J, Govek S, Darimont B, et al. (2015) Abstract 5053: Discovery of GDC-0810 a novel, non-steroidal selective estrogen receptor degrader with robust activity in pre-clinical models of endocrine-resistant breast cancer Cancer Research. 75: 5053-5053 |
| Joseph JD, Darimont B, Govek S, et al. (2014) Abstract 4757: A novel class of selective estrogen receptors degraders regresses tumors in pre-clinical models of endocrine-resistant breast cancer Cancer Research. 74: 4757-4757 |
| Joseph JD, Lu N, Qian J, et al. (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discovery. 3: 1020-9 |